Brief: Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA
03/03/2025 21:08
March 3 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL’S BLA SUBMISSIONS FOR TWO DENOSUMAB BIOSIMILARS ACCEPTED FOR REVIEW BY U.S. FDA AMNEAL PHARMACEUTICALS INC - FDA TARGET ACTION DATE FOR DENOSUMAB BIOSIMILARS IN Q4 2025 AMNEAL PHARMACEUTICALS INC - TO EXPAND TO SIX BIOSIMILARS BY 2027 AMNEAL PHARMA: THREE MORE BIOSIMILARS IN DEVELOPMENT Source text: ID:nBw2Kb0ZCa Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary